Sensus Healthcare (SRTS) Q3 2026 earnings review
Sensus Healthcare triples clinic shipments, but cash keeps falling
Sensus Healthcare, a maker of non-surgical skin cancer radiation machines, is replacing its lost top buyer with smaller clinics while still burning cash. Revenue fell 13% from a year ago to $6 million, helped by eight delayed second-quarter machines that finally closed. Excluding those eight units, chief executive Joseph Sardano tripled shipments to other buyers, and cheaper-to-build basic machines lifted gross margin to 55%.
| Shipments excluding Q2 carryover and lost customer | 18 units 6 units a year ago |
|---|---|
| Revenue | $6.0M -13% from a year ago |
| Gross margin | 55% 39.1% a year ago |
| Second-half revenue outlook | Unchanged Q3 alone topped H1's $5.7M |
⚖️ Verdict: 🟢 Bullish
The story got better because clinics outside the lost customer bought 18 machines on their own, up from 6 a year ago, including initial orders from two private equity-backed dermatology groups. One caution: cash fell another $2.3 million to $12.9 million because Sensus lent buyers $3 million over the first nine months through long-term payment notes to close sales.
The question now is whether new clinic demand can top 20 machines a quarter without delayed carryover units or heavy seller financing. Either the new Medicare payment codes drive self-sustaining cash sales in the fourth quarter, or unit volume drops back and forces the company to keep lending its own balance sheet to buyers. Fourth-quarter unit shipments and cash balances will settle it.
🐂 Bull Case
New Clinic Buyers Tripled Underlying Unit Shipments
Sensus Healthcare sells superficial radiotherapy (SRT) machines that treat non-melanoma skin cancer without surgery. After losing its biggest buyer late last year, chief executive Joseph Sardano said new Medicare payment codes effective in January have doctors focused on "how to bring SRT into their practices". The company still relies on replacing that lost buyer before its cash runs low.
Total revenue fell 13% from a year ago to $6.0 million, and by our math fell about 42% to $4.0 million without eight delayed second-quarter units. Even so, shipments to other customers tripled, helped by "initial system purchases by two large private equity-backed dermatology groups".
- Total machines shipped: 26, up from 16 a year ago
- Machines shipped excluding the 8-unit second-quarter carryover: 18, up from 6 to other customers a year ago
- Upfront sales excluding carryover and rentals: 15 machines, up from 6 to other customers a year ago by our math
The 18 standalone shipments fell two units short of management's 20-unit quarterly target without the carryover. Still, the jump from 6 to 18 units shows smaller clinics and dermatology groups are buying machines on the new payment codes.
What to watch: fourth-quarter unit shipments against management's 20-unit target. Because the fourth quarter has no delayed carryover units, hitting 20 shipments would prove new clinic demand can carry the business on its own.
Cheaper Machine Mix Lifted Gross Margin
Gross margin had fallen from 58.4% in 2024 to 34.8% last quarter as total sales shrank and servicing costs weighed on results. This quarter, customers bought more basic SRT-100 machines instead of pricier SRT-100 Vision systems, which include ultrasound imaging.
That product shift lowered the average selling price per machine, but the basic SRT-100 costs much less to build. Cost of sales — the cost of making and servicing the machines — dropped 15.4 percentage points of revenue, lifting gross margin to 55.0% from 39.1% a year ago. Sensus also cut research and development spending by 8.0 percentage points of revenue through "a reduction in lobbying cost and reduced headcount".
What to watch: whether gross margin stays above 50% in the fourth quarter without the eight delayed SRT-100 units. Holding that level would show the margin recovery comes from repeatable pricing rather than a one-time batch of basic machines.
🐻 Bear Case
Customer Financing and Losses Drained More Cash
Sensus has burned cash all year while sitting on a large stockpile of unsold machines. Even with eight delayed second-quarter units finally closing, cash and restricted cash fell another $2.3 million this quarter to $12.9 million, down from $22.1 million at the end of 2025.
- Cash and restricted cash: $12.9 million, down from $15.2 million in the second quarter
- Notes receivable (long-term customer payment plans): $3.3 million, up from $0.4 million at year-end by our math
- Inventory and prepaid inventory: $18.0 million, down from $19.1 million in the second quarter by our math
- Operating loss: $1.6 million, narrowed from $2.6 million a year ago
The company stopped prepaying for inventory and trimmed finished inventory slightly, which equals 6.6 quarters of cost of sales by our math. However, Sensus used its own balance sheet to finance customer purchases: total notes receivable grew by $3.0 million over the first nine months. When a device maker lends buyers the money to purchase its machines, shipment growth does not turn into immediate cash.
What to watch: cash and notes receivable on the fourth-quarter balance sheet. If notes receivable keep climbing while cash drops toward $10 million, the business will face tighter liquidity even if unit shipments meet management's target.
Usage Figures Stayed Hidden as Placements Grew
Sardano said Sensus is "developing additional revenue streams tied to system utilization, software and services" and focused on increasing machine usage. Under its Fair Deal Agreement program, the company places a machine at a clinic for no upfront payment and collects a fee each time a patient receives treatment.
Sensus shipped three machines under Fair Deal and rental contracts this quarter, up from zero a year ago, which held back upfront revenue. Yet for a second straight quarter, the release omitted the number of active Fair Deal clinics and how many treatments they performed. When a company highlights usage-based revenue but stops publishing the site and treatment numbers it used to report, investors cannot verify whether clinics are using the machines.
What to watch: the lease income footnote in the third-quarter 10-Q filing. It will show whether variable fee revenue from placed machines finally rose above the roughly $264,000 to $270,000 quarterly level seen in the first half.
Risks this quarter didn't answer
Four standing concerns received no update in the earnings release and depend on the conference call or the 10-Q filing.
- Fourth-quarter shipment outlook: the release gave no numeric target, leaving open whether management still expects at least 20 units in the fourth quarter.
- Full-year profitability goal: Sardano again spoke of "advancing our business toward sustainable profitability" after a $12.9 million nine-month net loss.
- Rising legal costs and the federal inquiry: general and administrative spending — overhead, legal and insurance costs — rose 9.7 percentage points of revenue on "higher legal and professional fees", with no update on the open Department of Justice billing inquiry.
- Customer concentration and bank credit limits: the release did not disclose how much revenue came from top buyers, overseas pricing, or whether $2.2 million of cash remains locked up to back the bank credit line.
👓 Other Themes
Asia-Pacific Marketing and Consumer Website Launch
Sensus launched TreatSkinCancer.com, a website to educate patients on non-surgical skin cancer treatments alongside its training programs for doctors. Management also worked to develop international markets across Asia-Pacific, including Australia, New Zealand, China and Hong Kong, and placed its 1,000th superficial radiotherapy system after the quarter ended. The press release did not report how many third-quarter units or dollars came from overseas buyers.
💲 Other KPIs
Rebounded 26.8% from last quarter and rose 17.3% from a year ago by our math, after falling for two straight quarters from its $852 thousand year-end peak. Deferred revenue — cash customers have paid upfront for service contracts or machine deposits — grew by $166 thousand this quarter as new machine shipments resumed.
Fell 16.5% from last quarter's $1.68 million and is down 76.8% from $6.04 million at the end of 2025. Accounts receivable — money owed by customers on standard short-term billing — stayed low even though revenue more than doubled from the second quarter, because more buyers used long-term notes receivable instead.
Unchanged from the second quarter and up 0.9% from 16.32 million a year ago. The medical device maker has neither bought back stock nor issued new shares to raise cash so far in 2026.
🔮 Guidance
Unchanged in the press release, which gave no new numeric outlook. Management previously planned for second-half revenue to beat the first half's $5.68 million, and third-quarter sales of $6.00 million already cleared that bar with the help of eight delayed second-quarter units.
❓ Key Questions
Does management still expect 20+ shipments in Q4?
The third quarter needed eight delayed second-quarter units to reach 26 shipments, leaving 18 standalone units. Without another carryover batch, hitting 20 units in the fourth quarter requires a step-up in new orders.
Why are long-term notes receivable growing so fast?
Total notes receivable jumped from $0.35 million at year-end to $3.34 million in the third quarter. Investors need to know the repayment terms and default risk on the loans Sensus is extending to buyers.
What are the active clinic and treatment counts for Fair Deal?
Sensus shipped three more shared-revenue and rental systems this quarter, but left out active site counts and treatment volumes for a second straight quarter despite higher Medicare payment rates.
What drove the 21% jump in general and administrative costs?
General and administrative expenses rose to $2.25 million on higher legal and professional fees even as research spending was cut by 39%. Management has not said whether those legal bills relate to the open federal billing inquiry.